1. Fiala MA, Foley NC, Zweegman S, Vij R, Wildes TM. The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma. J Geriatr Oncol 2020;11:1274–1278.

2. Panitsas F, Kothari J, Vallance G, et al. Treat or palliate: outcomes of very elderly myeloma patients. Haematologica 2018;103:e32–e34.

4. Bobin A, Gardeney H, Sabirou F, et al. The role of immunotherapy in non-transplant eligible multiple myeloma. Front Oncol 2020;10:676.

5. Qian X, Chen H, Xia J, Wang J, Zhou X, Guo H. Real-world clinical outcomes in elderly Chinese patients with multiple myeloma: a single-center experience. Med Sci Monit 2018;24:5887–5893.

6. Pawlyn C, Cairns D, Kaiser M, et al. The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia 2020;34:604–612.

7. Matsue K, Matsue Y, Fujisawa M, et al. Clinical features and treatment outcome of very elderly patients over 80 years old with multiple myeloma: comparison with patients in different age groups in the era of novel agents. Leuk Lymphoma 2016;57:110–115.

8. Xia J, Wang L, Zhou X, Wang J, Wang H, Guo H. Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice. J Int Med Res 2018;46:2230–2237.

9. Brink M, Groen K, Sonneveld P, et al. Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study. Blood Cancer J 2021;11:178.

10. Grant SJ, Wildes TM, Rosko AE, Silberstein J, Giri S. A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma. Cancer 2023;129:2023–2034.

11. Charliński G, Tyczyńska A, Małecki B, et al. Risk factors and causes of early mortality in patients with newly diagnosed multiple myeloma in a “real-world” study: experiences of the Polish Myeloma Group. Pol Arch Intern Med 2021;131:527–534.

12. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;Jun. 121(5):749–57.

13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.

14. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412–3420.

15. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 2015;33:2863–2869.

16. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.

17. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328–e346.

18. Ríos-Tamayo R, Sáinz J, Martínez-López J, et al. Early mortality in multiple myeloma: the time-dependent impact of comorbidity: a population-based study in 621 real-life patients. Am J Hematol 2016;91:700–704.

19. Antoine-Pepeljugoski C, Braunstein MJ. Management of newly diagnosed elderly multiple myeloma patients. Curr Oncol Rep 2019;21:64.

20. Cho HJ, Seo SK, Baek DW, et al. Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen. Yeungnam Univ J Med 2018;35:76–83.

21. Li J, Chan H. Management of multiple myeloma in older patients. EMJ Hematol 2021;9:69–81.

22. Dimopoulos MA, Kastritis E, Delimpasi S, et al. Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era. Eur J Haematol 2012;89:10–15.

23. Anagnostopoulos A, Gika D, Symeonidis A, et al. Multiple myeloma in elderly patients: prognostic factors and outcome. Eur J Haematol 2005;75:370–375.

24. Kim MK, Kim K, Min CK, et al. A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. Oncotarget 2017;8:37605–37618.

25. Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008;111:4039–4047.

26. Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015;125:2068–2074.

27. Engelhardt M, Domm AS, Dold SM, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 2017;102:910–921.

28. Engelhardt M, Dold SM, Ihorst G, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica 2016;101:1110–1119.

29. Dimopoulos MA, Terpos E. Lenalidomide: an update on evidence from clinical trials. Blood Rev 2010;24:Suppl 1. S21–S26.

30. Yhim HY, Park Y, Kim JA, et al. Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study. Korean J Intern Med 2024;39:501–512.